Cepheid launches MRSA/SA tests in Europe:
This article was originally published in Clinica
Cepheid has launched onto the European market two rapid tests for detecting methicillin-resistant staphylococcus aureus (MRSA) and staphylococcus aureus (SA). The tests are: Xpert MRSA/SA-blood cultures (BC), and Xpert MRSA/SA-skin and soft tissue infection (SSTI). They take just 50 minutes to deliver results, potentially allowing better patient management for those affected, said the firm. MRSA and SA are on the rise as two of the leading causes of hospital- and community-acquired infections, claimed the Sunnyvale, California company.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.